The research lines of our laboratory focus on identifying targets involved in the onset and development of neuropsychiatric disorders and addictions, aiming to improve diagnosis and pharmacological strategies. Special emphasis is placed on the role of the endocannabinoid system in regulating functional processes and its potential as a therapeutic target.
Recent efforts include studying the behavioral and neurobiological effects of perinatal exposure to substances such as alcohol and cannabis. A key methodological approach is the use of translational animal models that reproduce specific behavioral and neurobiological features of human disorders, facilitating the transfer of findings to clinical practice.
The group also has solid experience in handling clinical samples (post-mortem brain tissue, blood, lymphocytes) for biomarker discovery, using samples from biobanks and psychiatric services to conduct gene expression studies.
Within the RICORS framework, the group will contribute to several work packages. In WP4, we will study biological markers and behavioral traits linked to sex‑specific vulnerability to addiction, using models of prenatal and preconception exposure to THC and alcohol. These studies aim to understand sex‑dependent differences in addiction risk and guide the development of gender‑informed therapies.
In WP6, we will explore the biological and neurochemical mechanisms underlying addiction and its comorbidities by developing a spontaneous benzodiazepine withdrawal model in mice. This will allow us to identify biomarkers relevant to prolonged use and withdrawal, with the potential to inform clinical decision‑making and personalize treatment.
In WP7 and WP8, we will combine animal models and clinical gene expression data to analyze the behavioral and neurochemical changes associated with chronic drug use (alcohol and cocaine).
Lastly, we will actively support WP15 and WP16 through scientific outreach activities (e.g., ISABIAL’s Researchers’ Night and UMH’s “EUREKA!” event), institutional dissemination, and training initiatives aimed at professionals and patients, drawing on our expertise in translational neuropsychopharmacology and addictions.
